381 related articles for article (PubMed ID: 29487338)
1. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
[TBL] [Abstract][Full Text] [Related]
2. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Li LX; Fan LX; Zhou JX; Grantham JJ; Calvet JP; Sage J; Li X
J Clin Invest; 2017 Jun; 127(7):2751-2764. PubMed ID: 28604386
[TBL] [Abstract][Full Text] [Related]
3. Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
Liu L; Liu F; Guan Y; Zou J; Zhang C; Xiong C; Zhao TC; Bayliss G; Li X; Zhuang S
FASEB J; 2021 Jul; 35(7):e21715. PubMed ID: 34143514
[TBL] [Abstract][Full Text] [Related]
4. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
5. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
6. The histone methyltransferase Smyd2 is a negative regulator of macrophage activation by suppressing interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) production.
Xu G; Liu G; Xiong S; Liu H; Chen X; Zheng B
J Biol Chem; 2015 Feb; 290(9):5414-23. PubMed ID: 25583990
[TBL] [Abstract][Full Text] [Related]
7. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
8. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
[TBL] [Abstract][Full Text] [Related]
9. Kinectin 1 promotes the growth of triple-negative breast cancer via directly co-activating NF-kappaB/p65 and enhancing its transcriptional activity.
Gao L; Chen S; Hong M; Zhou W; Wang B; Qiu J; Xia J; Zhao P; Fu L; Wang J; Dai Y; Xie N; Yang Q; Huang HD; Gao X; Zou C
Signal Transduct Target Ther; 2021 Jul; 6(1):250. PubMed ID: 34219129
[TBL] [Abstract][Full Text] [Related]
10. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
11. Antagonizing binding of cell cycle and apoptosis regulatory protein 1 (CARP-1) to the NEMO/IKKγ protein enhances the anticancer effect of chemotherapy.
Venkatesh J; Sekhar SC; Cheriyan VT; Muthu M; Meister P; Levi E; Dzinic S; Gauld JW; Polin LA; Rishi AK
J Biol Chem; 2020 Mar; 295(11):3532-3552. PubMed ID: 32024692
[TBL] [Abstract][Full Text] [Related]
12. The lysine methyltransferase SMYD2 methylates the kinase domain of type II receptor BMPR2 and stimulates bone morphogenetic protein signaling.
Gao S; Wang Z; Wang W; Hu X; Chen P; Li J; Feng X; Wong J; Du JX
J Biol Chem; 2017 Jul; 292(30):12702-12712. PubMed ID: 28588028
[TBL] [Abstract][Full Text] [Related]
13. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
14. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of substrate methylation and inhibition of SMYD2.
Ferguson AD; Larsen NA; Howard T; Pollard H; Green I; Grande C; Cheung T; Garcia-Arenas R; Cowen S; Wu J; Godin R; Chen H; Keen N
Structure; 2011 Sep; 19(9):1262-73. PubMed ID: 21782458
[TBL] [Abstract][Full Text] [Related]
16. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
[TBL] [Abstract][Full Text] [Related]
17. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
18. SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
Wu L; Kou F; Ji Z; Li B; Zhang B; Guo Y; Yang L
Cell Death Dis; 2021 May; 12(5):439. PubMed ID: 33935284
[TBL] [Abstract][Full Text] [Related]
19. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
[TBL] [Abstract][Full Text] [Related]
20. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
